Chemomab Announces CM-101 Phase 2 SPRING Trial Results
Three Recent Announcements from: Pliant, NGM, and Chemomab PSC Partners is encouraged by the initial positive data from the CM-101 Phase...
top of page
News and Announcements
Choose a category:
Jul 21
Positive Update on Pliant’s INTEGRIS-PSC Phase 2a Trial
On July 15, 2024, Pliant Therapeutics announced positive results from their Phase 2a INTEGRIS-PSC trial for bexotegrast in treatment of...
Jun 21
Expanded Inclusion Criteria for Mirum’s VISTAS PSC Study for Pruritus Treatment
The following is a message from Mirum Pharmaceuticals regarding their VISTAS study for volixibat, a possible new treatment for...
Sep 29, 2023
Preliminary Results from INTEGRIS-PSC Phase 2a Clinical Trial
Exciting news about the Pliant Therapeutics PSC clinical trial preliminary results from their global INTEGRIS-PSC Phase 2a trial for...
Jun 23, 2023
PRIMIS (Phase 3 Study of Cilofexor) News from EASL Congress 2023
News from the EASLCongress 2023 meeting in Vienna From the "late-breaking" abstract session on June 24, 2023, results of the pre-planned...
Sep 27, 2022
PRIMIS (Phase 3 Study of Cilofexor) News
Statement From Gilead Sciences on September 27, 2022 Early Termination of Gilead-Sponsored Study GS-US-428-4194: A Phase 3, Randomized,...
Mar 1, 2021
Proof of Concept Phase 2 Trial of IMU-838 with Early Positive Results
A proof-of-concept Phase 2 trial conducted by Mayo Clinic and sponsored by Immunic has shown very early positive results. We hope that...
Jan 28, 2021
Clinical Trials Updated: PLN 74809 and Volixibat
The clinical trials resources page has been updated on 1/27/21 to reflect two clinical trials currently recruiting. PLN 74809: Phase 2a...
Sep 22, 2020
Nutrition Study Recruiting Now (US residents)
Check out this video invitation from PSC nutrition study Principal Investigator Dr. Josh Korzenik to participate in a diet and nutrition...
bottom of page